Idera Pharmaceuticals - Phase III data next month

Please take a look at IDRA with there P3 data coming next month:

Add it to your watchlist, take a look before or after to take a position.

*Huge upside possible very soon * Bakers Brothers largest holdings*
* Next month PH-3 advanced anti-PD-1 refractory melanoma data expected. Total market US & EU together ~1B but currently IDRA trading at ~200m Valuation
* FDA granted Orphan designation, preparing for the accelerated approval
* Enough cash in hand until Q1 of 2022 and current float is only 38m
* ~ 140m additional Private placement from two of the largest investors (BB and Pillar ) in place for the product launch
* MSS-CRC ph-2 data expected in Q3 2021
* Collaboration with Abbvie for Head & Neck data expected anytime
* Most advanced and undervalued TLR-9 company in the market , compare to CMPI MC of >300m with only Ph1/Ph2
* Pancreatic Cancer trial in progress
* IMO-2125 Ipi and Nivo in Patients With Advanced Cancers (PRIMO)
* IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma (INTRIM)
JPM 2021 https://jpmorgan.metameetings.net/events/healthcare21/sessions/35499-idera-pharmaceuticals/webcast?gpu_only=true&kiosk=true #investments